DF Gray

5.7k citations
17 papers · 4.5k indexed · 3 hit papers · h-index 11

Impact in

  • Hepatology top 0.1%
    • Hepatitis C virus research
    • Hepatitis Viruses Studies and Epidemiology
    • Hepatocellular Carcinoma Treatment and Prognosis
    • Liver Disease and Transplantation
    • Liver physiology and pathology
  • Epidemiology top 0.5%
    • Hepatitis B Virus Studies
    • Liver Disease Diagnosis and Treatment

Papers in

DF Gray

17 papers receiving 4.3k citations

Hit Papers

Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease 2004 · 1.7k citations
1.7k199820262007201650010001.5k

Peers

DF Gray
Comparison fields: 5 of 88
  • Hepatology 4.1k
  • Epidemiology 4.3k
  • Infectious Diseases 698
  • Microbiology 66
  • Virology 39
Replace Flavia Bortolotti with:
Flavia Bortolotti Italy
Denis Ouzan France
P Dentico Italy
Robert Schvarcz Sweden
Enea Spada Italy
M. Mizokami Japan
Rosendo Jardí Spain
M. S. Urdea United States
Jean‐Marie Huraux France
Maria de Medina United States
DF Gray relative to Flavia Bortolotti Italy Flavia Bortolotti's profile →
Citations per field
00.5×4.7×
Flavia Bortolotti · 1×
Citations per year

Countries citing papers authored by DF Gray

Since Specialization
Citations

This map shows the geographic impact of DF Gray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by DF Gray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites DF Gray more than expected).

Fields of papers citing papers by DF Gray

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by DF Gray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by DF Gray. The network helps show where DF Gray may publish in the future.

Co-authors

The 25 scholars most cited alongside DF Gray, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with DF Gray Line = papers co-authored together DF Gray links everyone, so they are left out of the graph.

All Works

17 of 17 papers shown
#Work
1
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Hit paper breakdown →
20041712
2
A One-Year Trial of Lamivudine for Chronic Hepatitis B
Hit paper breakdown →
19981427
3
Histological outcome during long-term lamivudine therapy
Hit paper breakdown →
2003583
4
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ).
2003440
5 2008117
6
Macrophage behaviour during the complaisant phase of murine pertussis.
196951
7 199839
8 199834
9 199922
10 196717
11 196711
12
The sequence of enhanced cellular activity and protective humoral factors in murine pertussis immunity.
196910
13
The acute phase response in autologous bone marrow transplantation.
19929
14 19987
15 19983
16 20013
17 20061

About DF Gray

DF Gray is a scholar working on Hepatology, Microbiology, Epidemiology, Infectious Diseases and Molecular Medicine, having authored 17 papers that have together received 4.5k indexed citations. Recurring topics across this work include Hepatitis C virus research (10 papers), Hepatitis B Virus Studies (9 papers), Liver Disease Diagnosis and Treatment (5 papers), HIV/AIDS drug development and treatment (3 papers), Bacterial Infections and Vaccines (3 papers), Tuberculosis Research and Epidemiology (2 papers), Influenza Virus Research Studies (2 papers) and Systemic Lupus Erythematosus Research (2 papers). The work is most often cited by research in Hepatology (4.1k citations), Epidemiology (4.3k citations), Infectious Diseases (698 citations), Microbiology (66 citations) and Virology (39 citations). DF Gray has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include Sally L. Stephenson, Joseph J.�Y. Sung, Cha‐Ze Lee, Geoffrey C. Farrell, Tawesak Tanwandee, Yun‐Fan Liaw, Hon K. Yuen, Jonathan S. Dixon, Oliver N. Keene and Wan Cheng Chow. Their work appears in journals such as Journal of Hepatology, Gastroenterology, Immunology and Cell Biology, New England Journal of Medicine and European Journal of Gastroenterology & Hepatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026